Advarra
MARCH 31, 2023
Among the various regulatory bodies providing oversight on clinical research, only the institutional biosafety committee (IBC) has a purview specific to research involving engineered genetic materials. The post Risk Assessment for use of Engineered Genetic Materials in Clinical Research appeared first on Advarra.
Cloudbyz
NOVEMBER 3, 2021
Biosamples and biomarkers are the core basis for much of the work done in the clinical research industry and proficient Human Biosample Management (HBSM) is necessary to procure reliable biosamples. Muscle tissues, nerve tissues, cell lines, blood cells, stem cells, and more. Sample Backup. Let’s use the easiest example of a sample.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 7, 2022
Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. However, Dr. Bahassi reported that the selection of CTCs using this method is often not very efficient and the CTC population is usually highly contaminated with leukocytes.
Drug Discovery World
AUGUST 10, 2022
Although this type of contamination has not yet been reported in humans, RCVs can form rapidly growing T cell neoplasms, another type of cancer. To prevent this from happening, the FDA recommends that manufacturers test clinical vector lots, manufactured cell products, and patients who have received treatment with CAR T cell therapy 14.
XTalks
SEPTEMBER 14, 2020
Below are some free webinars you can register for that have delved into the topic: Continuing Clinical Research Innovations After COVID-19. The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like. Addressing the Rapidly Evolving Vaccine Development Landscape.
Expert insights. Personalized for you.
52 
Let's personalize your content